Non-Hodgkin lymphoma (NHL) is a cancer that develops in white blood cells, called B-cells. The most common types of NHL are diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). 

DLBCL is a fast-growing lymphoma, but can often respond well to treatment. More than 50% of newly diagnosed patients with DLBCL are cured(1) with current treatments. FL is a more slow-growing cancer that is considered incurable with existing therapies(2) . The most common treatments for DLBCL and FL involve chemotherapy and monoclonal antibodies.

Both DLBCL and follicular lymphoma can affect a person of any age; however, they occur most commonly in older people with an average age of diagnosis in the mid-60s.

(1) Friedberg JW, Hematology, 2011.
(2) Ghielmini M, Annals Oncology, 2010.

Learn More about Tazemetostat

Clinical Trial in DLBCL and FL

Epizyme is enrolling adult patients (18 years and older) with either DLBCL or FL that has relapsed (when the disease or symptoms returns) or is refractory (resistant) to prior treatment in a Phase 2 clinical trial.

For more detailed information on this trial, please visit: https://clinicaltrials.gov/ct2/show/NCT01897571